NewLimit Blog

NewLimit Blog

Home
Archive
About
Announcing NewLimit: a company built to extend human healthspan
Aging is something that affects all of us, yet there are only a couple organizations in the world that are applying industrial scale to investigating…
 • 
Brian Armstrong
 and 
Blake Byers
NewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investors
NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging
 • 
Brian Armstrong
, 
Blake Byers
, 
Greg Johnson
, and 
Jacob C. Kimmel
NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others
NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming
 • 
Brian Armstrong
, 
Blake Byers
, 
Cathy O'Hare
, and 
Jacob C. Kimmel
January // February 2025 Progress Update
Therapeutic beginnings
 • 
Jacob C. Kimmel
2024 Year in Review
Restoring youthful function
 • 
Jacob C. Kimmel
2023 Year in Review
Construction ends. The search begins.
 • 
Jacob C. Kimmel
May // June 2025 – Progress Update
Therapeutic pleiotropy
 • 
Jacob C. Kimmel
September // October 2024 Progress Update
In chimerico reprogramming
 • 
Jacob C. Kimmel
Developing reprogramming therapies
Engineering a new class of medicines inspired by the biology development & regeneration
 • 
Jacob C. Kimmel
May // June 2024 Update
Reversing phenotypic age
 • 
Jacob C. Kimmel
July // August 2024 Progress Update
Completing the discovery cycle
 • 
Jacob C. Kimmel
2025 NewLimit Progress Update
Live!
 • 
Jacob C. Kimmel
© 2025 NewLimit Inc.
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture